Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial

IMPORTANCE: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches. OBJECTIVE: To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jing, Chen, Jiali, Miao, Miao, Zhang, Ruijun, Cheng, Gong, Wang, Yifan, Feng, Ruiling, Huang, Bo, Luan, Huijie, Jia, Yuan, Jin, Yuebo, Zhang, Xiaoying, Shao, Miao, Wang, Yu, Zhang, Xia, Li, Jing, Zhao, Xiaozhen, Wang, Han, Liu, Tian, Xiao, Xian, Zhang, Xuewu, Su, Yin, Mu, Rong, Ye, Hua, Li, Ru, Liu, Xu, Liu, Yanying, Li, Chun, Liu, Huixin, Hu, Fanlei, Guo, Jianping, Liu, Wanli, Zhang, Wen-Bin, Jacob, Alexander, Ambrus, Julian L., Ding, Changhai, Yu, Di, Sun, Xiaolin, Li, Zhanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650609/
https://www.ncbi.nlm.nih.gov/pubmed/36355371
http://dx.doi.org/10.1001/jamanetworkopen.2022.41451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650609/
https://www.ncbi.nlm.nih.gov/pubmed/36355371
http://dx.doi.org/10.1001/jamanetworkopen.2022.41451

Ejemplares similares